- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Regeneron and Mammoth announce gene editing partnership worth $370m per target | ||
| Fr | BeiGene's Tizveni receives EC approval to treat non-small cell lung cancer | ||
| Fr | Biogen's tocilizumab biosimilar Tofidence recommended by CHMP to treat arthritis and COVID-19 | ||
| Fr | Sanofi presents positive phase 3 results for rilzabrutinib in immune thrombocytopenia | ||
| Fr | The princess, the queen and the grandfather | ||
| Do | J&J and Legend's Carvykti receives EC approval to treat relapsed and refractory multiple myeloma | ||
| Do | Astellas announces EC approval of Xtandi for expanded prostate cancer use | ||
| Do | AI drug discovery biotech Xaira Therapeutics launches with over $1bn in committed funding | ||
| Do | Novartis' Lutathera receives FDA approval to treat neuroendocrine tumours in paediatric patients | ||
| Do | FDA grants Day One's Ojemda accelerated approval for paediatric low-grade glioma | ||
| Do | Current trends and the renaissance of Alzheimer's drug development | ||
| Mi | Novartis' targeted combination therapy recommended by NICE to treat childhood brain tumours | ||
| Mi | Incyte announces agreement to acquire Escient Pharmaceuticals for $750m | ||
| Mi | AstraZeneca's Voydeya granted EC approval to treat rare blood disease PNH | ||
| Mi | FDA approves ImmunityBio's Anktiva for non-muscle invasive bladder cancer | ||
| Mi | Eisai and BioArctic sign research evaluation agreement for potential new Alzheimer's treatment | ||
| Mi | Rare diseases - raising awareness, listening to patients, making a difference | ||
| Di | Pfizer's antibiotic combination received EC approval to treat multidrug-resistant infections | ||
| Di | UCB's Bimzelx granted EC approval to treat hidradenitis suppurativa in adults | ||
| Di | Takeda's subcutaneous Entyvio approved by FDA as Crohn's disease maintenance therapy | ||
| Di | Afon Technology's glucose monitoring device secures Junkosha award plus $25,000 prize | ||
| Di | Budget burnout: avoiding the pitfalls of outdated engagement strategies | ||
| Di | Fox&Cat relaunches with industry-first efficiency and effectiveness planning framework ADAPT | ||
| Mo | Ipsen and Skyhawk announce $1.8bn partnership to advance rare neurological disease therapies | ||
| Mo | NICE recommends Menarini's Nexpovio combination to treat multiple myeloma |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
